ISMP Medication Error Report Analysis

Aggrastat-Argatroban Mix-ups

Don't Expect Radiofrequency Identification Stock Systems To Be Perfect

Paralyzed by Mistakes: Reassess the Safety of Neuromuscular Blockers in Your Facility

Michael R. Cohen, RPh, MS, ScD, and Judy L. Smetzer, RN, BSN†*

These medication errors have occurred in health care facilities at least once. They will happen again—perhaps where you work. Through education and alertness of personnel and procedural safeguards, they can be avoided. You should consider publishing accounts of errors in your newsletters and/or presenting them at your inservice training programs.

Your assistance is required to continue this feature. The reports described here were received through the Institute for Safe Medication Practices (ISMP) Medication Errors Reporting Program. Any reports published by ISMP will be anonymous. Comments are also invited; the writers' names will be published if desired. ISMP may be contacted at the address shown below.

Errors, close calls, or hazardous conditions may be reported directly to ISMP through the ISMP Web site (www.ismp.org), by calling 800-FAIL-SAFE, or via e-mail at ismpinfo@ismp.org. ISMP guarantees the confidentiality and security of the information received and respects reporters' wishes as to the level of detail included in publications.

AGGRASTAT-ARGATROBAN MIX-UPS

We are aware of 3 mix-ups in 2 hospitals that resulted in the pharmacy dispensing infusions of AGGRASTAT (tirofiban) instead of argatroban. Both of these high-alert medications are available in 250 mL premixed bags, although Aggrastat is 12.5 mg/250 mL (a premixed 5 mg per 100 mL is also available) and argatroban is 250 mg/250 mL. In 2 of the cases, the error reached the patient and was not discovered until the next dose was due. Bedside barcode scanning was in place at one of the hospitals, but pharmacy printed and affixed a patient label with a barcode for argatroban on an Aggrastat bag. A nurse scanned the pharmacy label, which confirmed

that argatroban was printed on the pharmacy label, when the drug in the bag was actually Aggrastat.

The hospital also believes that look-alike drug names played a role in the mix-up, so they've started using their own tall-man letters for these drugs—aggraSTAT and arGATROban.

Part of the problem was that these drugs were stored close to each another; they've since been moved so they are no longer side-by-side. Also, the pharmacy no longer prints a barcode on labels for Aggrastat or argatroban. They have the nurse scan the actual manufacturer's barcode on the bag label. In one of the mix-ups, pharmacy had a process in place to scan the manufacturers' barcodes before dispensing, but

*President, Institute for Safe Medication Practices, 200 Lakeside Drive, Suite 200, Horsham, PA 19044; phone: 215-947-7797; fax: 215-914-1492; e-mail: mcohen@ismp.org; Web site: www.ismp.org. †Vice President, Institute for Safe Medication Practices, Horsham, Pennsylvania.

2 staff members skipped the step and the system still allowed the drug to be dispensed from the pharmacy. A hard stop requirement for scanning the product is needed to address this type of omission.

Finally, a pop-up warning at the point of administration now alerts the nurse to visually verify that he/she is hanging the correct drug—argatroban or Aggrastat.

DON'T EXPECT RADIOFREQUENCY IDENTIFICATION STOCK SYSTEMS TO BE PERFECT

A hospital that started using radiofrequency identification (RFID) technology to refill various emergency kits (eg, anesthesia, rapid sequence intubation, stroke) reported some problems they've encountered with the system. In the past, pharmacy technicians had to manually inspect each medication in the kit to know what needed to be replaced or exchanged due to expiration. With RFID, each item is tagged with the NDC number, lot number, and expiration date. Anything missing can then be identified via an RFID scanner. This helps to improve the efficiency of checking kits. An entire tray can be accounted for at once. Still, these systems are not perfect.

One problem occurs when a kit is opened and a medication is used and then returned to the kit, which is sent back to pharmacy. When pharmacy scans the used kit for missing items, the technology doesn't pick up on the fact that the opened vial is still in the kit, therefore the empty or partially used vial is not replaced. The failure to replace an empty vial can cause a delay in therapy. The hospital reported that this happened when rocuronium was not available in a kit as a case was ready to start.

Other hospitals have also reported problems. For example, an open vial of propofol was missed when it was returned with a used anesthesia kit. Another hospital reported a situation in which an RFID tag fell off the product and remained in the code cart tray after patient resuscitation. Since the drug tag was still there, the RFID system indicated that the drug was still there and the drug was not replaced. Scanning also doesn't detect special arrangements of vials. As long as the right number of vials is present and they have not expired, the system won't detect if these are placed in the wrong bin.

The bottom line with RFID technology is that it doesn't solve the human element; people can leave an RFID tagged—but used—vial in the kit. Basically, each vial in the kit still has to be visually inspected to ensure that it hasn't been used and placed back into the kit. Of course, such problems are not unique to an

RFID tag system. The same issues could occur with manual systems when a cursory review of code tray contents fails to detect an empty or partially filled vial. The RFID tag system is a step in the right direction, but not a complete solution to a tedious process.

PARALYZED BY MISTAKES: REASSESS THE SAFETY OF NEUROMUSCULAR BLOCKERS IN YOUR FACILITY

Neuromuscular blocking agents are high-alert medications because of their well-documented history of causing catastrophic injuries or death when used in error. These drugs are used during tracheal intubation, during surgery of intubated patients, and to facilitate mechanical ventilation of critically ill patients. However, neuromuscular blockers have been inadvertently administered to both adult and pediatric patients who were not receiving proper ventilatory assistance. Because neuromuscular blockers paralyze the muscles that are necessary for breathing, some patients have died or sustained serious, permanent injuries if the paralysis was not witnessed by a practitioner who could intervene.

After a patient receives a neuromuscular blocker, progressive paralysis develops, initially affecting the small muscle groups such as the face and hands, then moving to larger muscle groups in the extremities and torso until all muscle groups are paralyzed and respiration ceases. However, full consciousness remains intact, and patients can experience intense fear when they can no longer breathe. They can also sense pain. The experience can be horrific for patients and can lead to psychological trauma, including post-traumatic stress disorder.¹

The ISMP National Medication Errors Reporting Program (MERP) has received more than 100 reports of errors involving neuromuscular blockers. However, the true incidence of injuries from erroneous administration of neuromuscular blockers is much higher than reflected in our error-reporting program. Whereas some errors have occurred during anesthesia in the operating room (OR), many have taken place in emergency departments (EDs), interventional radiology departments, intensive care units (ICUs), and other medical, surgical, and psychiatric units.

The most common type of error with neuromuscular blockers appears to be administration of the wrong drug. A 2009 analysis of 154 events over a 5-year period showed that a neuromuscular blocker was not the intended drug in approximately half of all wrong drug errors.² Practitioners thought they were administering a different drug, so patients may

not have been supported with mechanical ventilation. More than 80% of these wrong-drug errors reached the patient, and approximately a quarter resulted in patient harm—a rate significantly higher when compared to less than 1% of events causing harm with all other wrong-drug errors during the same study period.²

Errors with neuromuscular blockers can be attributed to one or more common causes. The following provides a sampling of the causes of errors with examples.

Look-Alike Packaging and Labeling

An ED nurse administered pancuronium instead of influenza vaccine to several patients. The vials were the same size, and the labels were quite similar. The look-alike vials had been stored next to each other in the refrigerator. The patients experienced dyspnea and respiratory depression but, fortunately, sustained no permanent injuries.

Several practitioners reported concern regarding the similarity of vials of flumazenil 0.5 mg/5 mL and vecuronium 10 mg from NOVAPLUS once the different colored caps have been removed (see **Figure 1**, left). Both may be stored in procedural areas, increasing the risk of a mix-up.

Similar colors and label graphics contribute to Mylan's vecuronium 20 mg and vancomycin 1 g vials

looking alike (see **Figure 1**, right), especially with the caps removed. Both contain white lyophilized powder that requires reconstitution.

Look-Alike Drug Names

NARCAN (naloxone) and NORCURON (vecuronium) have been confused with written and verbal orders. In one case, a nurse transcribed a verbal order for Narcan correctly, but a pharmacist misread the order and dispensed Norcuron. The nurse thought Norcuron was the generic name for Narcan and administered it. In another case, a physician prescribed Narcan, but an intensive care unit (ICU) nurse did not recognize the drug on the automated dispensing cabinet (ADC) screen because it was listed by its generic name. She intended to ask a coworker for Narcan's generic name, but she mistakenly asked for the generic name of Norcuron. She then removed vecuronium from the ADC and administered it. The patient arrested, was resuscitated and placed on a ventilator, and later fully recovered.

Unsafe Mnemonics

During pharmacy entry of an order for an infusion of cisplatin, the mnemonic computer rule after entering "cis" completed the drug field name with cisatracurium, generating a label for the neuromuscular blocker, which was prepared and dispensed.³

Figure 1. Once the caps are removed, these vials look very similar. However, a mix-up could be catastrophic.

Drug Administration After Extubation

A ventilated ICU patient was receiving vecuronium and a potassium chloride infusion. After the patient was extubated, an infusion bag containing vecuronium remained in the room and was mistaken as a potassium chloride infusion. Soon after the medication was started, the patient arrested and required intubation and ventilation for 6 more hours.

Unlabeled and Mislabeled Syringes

Prefilled syringes of saline flushes were not available in the ED, so nurses prepared a supply each day from multiple-dose vials. Vecuronium had recently been prepared for a trauma patient in the ED, but it was not used. The syringe was not labeled and was inadvertently placed with the saline flush syringes. The syringe containing vecuronium was later used to flush the IV line of a 3-year-old child. The child became flaccid and stopped breathing. She was quickly intubated and ventilated, so permanent harm was averted.

An anesthesiologist was interrupted while preparing syringes of midazolam and rocuronium.³ When he returned, he administered the contents of one syringe to a patient in the holding area, believing it contained midazolam. He was again called away, and when he returned, the patient was unresponsive. The patient was intubated and given a reversal agent, and surgery was postponed. It was later determined that the anesthesiologist had administered the syringe containing rocuronium.

A pharmacy prepared batches of succinylcholine and ePHEDrine in ready-to-use syringes for the labor and delivery unit. The technician prepared both correctly and placed them in a divided bin to be checked. Either the labels were placed in the wrong compartments, or they were placed in the correct compartments but were applied to the wrong syringes. A dose of succinylcholine was administered IV instead of ePHEDrine to treat hypotension. The patient experienced respiratory arrest but was resuscitated successfully.

Unsafe Storage

Atracurium was administered instead of hepatitis B vaccine to several infants who developed respiratory distress. One infant sustained permanent injury and another died. Neuromuscular blockers had never been available as unit stock in the nursery. An anesthesiologist from a nearby OR had placed the atracurium vial in the nursery refrigerator near look-alike vaccine vials. Similar mix-ups with vaccines continue to occur.⁴

In a pediatric ICU, a respiratory therapist obtained what he thought was a sterile water vial to prepare a nebulizer treatment. As he was piercing the stopper, he noticed that he had accidentally grabbed a vial of atracurium that someone had inadvertently returned to a respiratory box in the refrigerator.

Orders Entered into Wrong Electronic Health Record

A medical resident electronically prescribed vecuronium for the wrong patient with a similar name, who was located on a medical unit. The correct patient was ventilated and in the ICU. The pharmacist and technician did not question the infusion for a medical unit patient. An independent double-check was carried out by 2 nurses before administration, but neither nurse was aware that the patient required ventilation with this drug.

Knowledge Deficit About Drug Action and Required Ventilation

An ED physician gave a verbal order for a trauma patient to receive vecuronium and midazolam, which were administered prior to intubation. He then mistakenly entered electronic orders for these medications into another patient's record. An ED nurse administered the medications to the patient without recognizing that vecuronium would paralyze the respiratory muscles. After she left the room, the patient arrested. The ED team responded, but the patient could not be resuscitated.

Syringe Swaps

Succinylcholine was inadvertently administered instead of fentaNYL prior to the induction of anesthesia.⁵ The anesthetist had drawn up both drugs into 2 mL syringes and had applied a blank red and black label on the succinylcholine syringe and a manufacturer-supplied label to the fentaNYL syringe, which was also red and black—a label color in anesthesia reserved for neuromuscular blockers. The anesthetist picked up the succinylcholine syringe, believing it contained fentaNYL based on its position on the table.

A patient became unresponsive in the holding area after IV administration of cisatracurium instead of midazolam. The patient was ventilated and the surgery proceeded. Two additional syringe swaps involving cisatracurium outside the OR were reported.^{3,6}

Reversal Agent Not Available

Several practitioners have reported that reversal agents (ie, neostigmine, sugammadex) for neuromuscular blockers have not been available when needed in the OR and elsewhere. One reporter said the reversal agents were in a locked cabinet and not accessible.

Residual Drug in Tubing

In a post-anesthesia care unit (PACU), a nurse administered a dose of HYDROMorphone through an IV line in the patient's left arm. The IV line in the patient's right arm was clamped, so the nurse opened the line and flushed it. About 2 minutes later, the patient stopped moving and breathing, and his oxygen saturation fell to 40%. Anesthesia was called, and the problem was thought to be caused by flushing the remaining rocuronium in the IV tubing into the patient. Neostigmine was administered for blockade reversal.

Dose or Rate Confusion

Mental mix-ups have led to numerous dosing errors. For example, rocuronium was infused at the rate intended for cisatracurium, and several patients received the wrong dose of rocuronium because the physician dosed it in mcg/kg/hour, not mcg/kg/minute.

Recommendations

Serious adverse events continue to occur with neuromuscular blockers when they are used without adequate safeguards. Although the causes are varied, many of the most harmful or fatal errors involve the accidental administration of a neuromuscular blocker when another drug is intended. Thus, adherence to proper ordering, storage, selection, preparation, and administration is paramount. Neuromuscular blockers are also a focus of Best Practice 7 in the ISMP 2016-2017 Targeted Medication Safety Best Practices for Hospitals, which aims to promote safe storage of neuromuscular blockers.⁷ To reduce the risk of harm from neuromuscular blockers, consider the following recommendations. The primary recommendations should be given the highest priority for action by hospitals and surgery centers. The secondary recommendations address the common causes of medication errors that are not necessarily unique to neuromuscular blockers.

Primary Recommendations

Assess labeling and packaging. Require a medication safety officer (MSO) and an anesthesia staff member to evaluate any new neuromuscular blocker's packaging and labeling prior to procurement, and introduce auxiliary label enhancements and education, if necessary, before distribution.⁶ Use brands of neuromuscular blockers that clearly differentiate the vials from other products via warnings on the label, vial cap, and metal ferrule around the rubber stopper. (All manufacturers of these agents are required to provide cautionary labeling. The development of a universal symbol for neuromuscular blockers remains to be determined.⁸) Avoid ampuls, which have small, hard-to-read labels.

Standardize prescribing. Outside the OR or procedural areas, orders for neuromuscular blockers should only be part of an intubation protocol or an order set to maintain a specific level of paralysis while the patient is on a ventilator. Do not accept neuromuscular blocker orders for "use as needed for agitation." Include the need for ventilation support during and after administration and automatic discontinuation of these agents in electronic records after extubation and removal from a ventilator. Completely disallow orders to "resume the same medications" upon patient transfer.

Use clear terminology. Always refer to these drugs as "neuromuscular blockers" or "paralyzing agents." Never call them "muscle relaxants."

Build computer reminders. Build alerts in the computer system to verify the patient's location when neuromuscular blocker orders are being prescribed or entered/verified by pharmacy. If the patient is not in a critical care unit, ED, OR, or invasive procedure area, prescribers should verify that they are entering the order into the correct patient profile, and pharmacists should question the order and verify ventilatory assistance before dispensing the drug. If possible, establish computerized cross-checking of the patient's location when entering neuromuscular blocker orders (as with other drugs limited to administration on a specific unit). Cautionary messages may also appear on ADC screens.

Limit access. Eliminate the storage of neuromuscular blockers in areas of the hospital where they are not needed.⁷ Allow unit stock only in the OR, ED, and critical care units where patients can be properly ventilated and monitored. Consider limiting the number of neuromuscular blockers on formulary,

and eliminate storage from pharmacy stock when possible. Regularly review these storage areas, both inside and outside of the pharmacy, including agents that require refrigeration, and consider the potential for mix-ups. Limiting access to these products is a strong deterrent to inadvertent use.

Segregate storage. Segregate, sequester, and differentiate all neuromuscular blockers from other medications, wherever they are stored in the organization.⁷ In areas where they are needed, place neuromuscular blockers in a lidded box or in a rapid sequence intubation (RSI) kit. One option is a highly visible red-orange storage container available commercially (www.ismp.org/sc?id=458). If neuromuscular blockers must be stored in ADCs, keep them in separate lidded pockets, away from other drugs. Also segregate neuromuscular blockers from all other medications in the pharmacy by placing them in separate lidded containers in the refrigerator or another secure, isolated storage area. Organize anesthesia carts and trays to avoid the proximity of look-alike vials, syringes, or bags, and display the labels so they are readily visible.

Affix warning labels. Place auxiliary labels on all storage bins and final medication containers (eg, vials, syringes, IV bags) of neuromuscular blockers that state “WARNING: PARALYZING AGENT— CAUSES RESPIRATORY ARREST” to clearly communicate that respiratory paralysis will occur and ventilation is required. The warning labels should not cover important label information. For infusions, one hospital system also places a warning on a port tag that will be seen by nurses when they spike the bag to attach tubing. The use of shrink-wrap sleeves is questionable because they make all vials look alike.

Dispense from pharmacy. For nonurgent doses in the OR or ED and continuous infusions in the ICU, dispense neuromuscular blockers from the pharmacy in the most ready-to-use form. The Anesthesia Patient Safety Foundation recommends the use of labeled, prefilled syringes and prepared infusions of neuromuscular blockers (and other anesthesia drugs) dispensed by pharmacy, commercially available, or outsourced rather than self-prepared syringes or infusions.⁹ Properly labeled, prefilled syringes have the potential to improve system safety, reduce syringe swaps, and enhance work efficiency.¹⁰ Never dispense a neuromuscular blocker to a unit that cannot support mechanical ventilation.

Verify neuromuscular blockers. Remind practitioners that reading labels is the first defense to avoid an error. Implement point-of-care barcode scanning

to verify neuromuscular blockers and patients before administration. In the OR and procedural areas, if barcode scanning is not undertaken, consider alternative verification systems including speakers and touch screens that provide automatic auditory and visual verification of drugs and important alerts prior to administration.^{11,12}

Use smart infusion pumps. Administer all neuromuscular blocker infusions via a programmable smart infusion pump utilizing dose error-reduction software. Smart infusion pumps should be programmed to allow selection of a neuromuscular blocker infusion only in patient care areas capable of caring for ventilated patients receiving such agents. When a neuromuscular blocker is selected in units where ventilation is possible, a clinical advisory warning should note that the drug paralyzes the respiratory muscles, and the nurse must confirm that the patient is on mechanical ventilation. The flow rate of infusions of neuromuscular blockers should be presented and entered into the pump using the same standard dosing units prescribers use (eg, mcg/kg/minute vs mcg/kg/hour).

Secondary Recommendations

Reduce the risk of IV admixture errors. Adopt IV workflow technology that utilizes barcode scanning of products during pharmacy IV admixture preparation. Systems that support barcode scanning and gravimetrics can ensure proper drug selection and correlation to individual patient’s orders. To be maximally effective, the system should be utilized for all compounded admixtures. Please refer to the ISMP Guidelines for Safe Preparation of Sterile Compounds (www.ismp.org/sc?id=461) for details (currently being updated).

Reduce the risk of batching errors. Compound one drug batch at a time, and verify and label the products before beginning any subsequent single or batch preparations.

Reduce unsafe mnemonics. Review order entry systems to identify problematic mnemonic auto-fill entries and label generation associated with neuromuscular blockers, and implement safer computer rules for mnemonics when indicated.³

Provide warnings on pharmacy labels. Ensure that pharmacy work labels and infusion/product labels for neuromuscular blockers are clear, accurate, and contain all necessary warnings.³

Require proper labeling. Promote accurate labeling of all infusions and syringes containing neuromuscular blockers both in the OR and in

patient care locations outside the OR. (When possible, prepared and labeled syringes and bags should be provided.)

Provide access to reversal agents. Ensure all appropriate reversal agents for neuromuscular blockade are available to qualified staff who might need them in an emergency. In protocols, identify who is permitted to administer the reversal agent in an emergency and provide readily available instructions for administration.⁷

Flush the line. If a neuromuscular blocker has been administered, all of the drug should be flushed from the IV line or the line changed (and any source container removed) prior to extubation.

Timely dispensing and prompt removal. Pharmacy should practice just-in-time dispensing of neuromuscular products when possible to avoid unnecessary access to these products before use. When the drugs are no longer needed, place unused/partially used vials, bags, and syringes of neuromuscular blockers in a sequestered bin for return to the pharmacy. Unused patient-specific doses should be destroyed/discarded after the patient has been extubated or the drug has been discontinued.

Increase awareness. Educate staff about the risk of serious errors with these high-alert drugs. Provide staff with a list of both generic and brand names for all neuromuscular blockers available at your location, and include usual dosages and any special guidelines associated with preparation, distribution, administration, and monitoring. Also use the information above to assess your safety practices.

Verify competency. Establish a formal training program and competency verification process for practitioners involved in preparing, dispensing, and administering neuromuscular blockers.³ These drugs should only be administered by staff with experience in maintaining an adequate airway and respiratory support and only in units where intubation and respiratory support can be provided.

REFERENCES

1. Frazee EN, Personett HA, Bauer SR, et al. Intensive care nurses' knowledge about use of neuromuscular blocking agents in patients with respiratory failure. *Am J Crit Care*. 2015;24(5):431-439.
2. Pennsylvania Patient Safety Authority. Neuromuscular blocking agents: Reducing associated wrong-drug errors. *PA Patient Saf Advis*. 2009;6(4):109-114.
3. Santell JP. Medication errors involving neuromuscular blocking agents. *Jt Comm J Qual Patient Saf*. 2006;32(8):470-475,417.
4. Roberts L. At least 15 children in Syria die in measles immunization campaign. *Science*. September 18, 2014. <http://www.sciencemag.org/news/2014/09/least-15-children-syria-die-measles-immunization-campaign>
5. Parry M, Morris S. Critical incident involving syringe labels. *Anaesthesia*. 2007;62(1):95-96.
6. Graudins LV, Downey G, Bui T, Dooley MJ. Recommendations and low-technology safety solutions following neuromuscular blocking agent incidents. *Jt Comm J Qual Patient Saf*. 2016;42(2):86-91.
7. ISMP. 2016-2017 Targeted medication safety best practices for hospitals. 2016. www.ismp.org/sc?id=417
8. ISMP Canada. Neuromuscular blocking agents: Sustaining packaging improvements over time. *ISMP Canada Safety Bulletin*. 2014;14(7):1-5.
9. Brown LB. Medication administration in the operating room: New standards and recommendations. *AANA J*. 2014;82(6):46546-9.
10. Yang Y, Rivera AJ, Fortier CR, Abernathy JH 3rd. A human factors engineering study of the medication delivery process during an anesthetic: Self-filled syringes versus pre-filled syringes. *Anesthesiology*. 2016;124(4):795-803.
11. Graudins VL, Downey G, Bui T, Dooley MJ. Neuromuscular blocking agents: High-alert medications with ongoing risks of error. *Anaesth Intensive Care*. 2015;43(2):270-271.
12. Merry AF, Webster CS, Hannam J, et al. Multimodal system designed to reduce errors in recording and administration of drugs in anaesthesia: Prospective randomised clinical evaluation. *BMJ*. 2011; 343:d5543. ■